BRIEF-Albireo Pharma to present final results of phase 2 study of A4250 in children with cholestatic liver disease

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.